Stable pharmaceutical formulation comprising HMC-CoA reductase inhibitor

A technology of reductase inhibitors and drugs, which is applied in the field of solid drug formulations and can solve problems such as side effects
CN1330538AInactive Publication Date: 2002-01-09LEK PHARMA & CHEM

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
LEK PHARMA & CHEM
Publication Date
2002-01-09
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilised by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a stable solid pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. More precisely, the present invention relates to the new stable solid pharmaceutical formulation containing as an active ingredient a HMG-CoA reductase inhibitor, such as atorvastatin, pravastatin, fluvastatin and cerivastatin or pharmaceutically acceptable salts thereof.
Need to check novelty before this filing date? Find Prior Art

Description

field of invention

[0001] The invention relates to a new stable solid medicine formula, which is especially suitable for treating hypercholesterolemia and hyperlipidemia. In particular, the present invention relates to a novel stable solid pharmaceutical formulation containing active substances HMG-CoA reductase inhibitors such as atorvastatin, pravastatin, fluvastatin and cervastatin, or pharmaceutically active salts. Background of the invention

[0002] Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, fluvastatin and cervastatin and their derivatives and analogs are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. They are mainly produced by fermentation with microorganisms belonging to different species of Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium. Some are chemically synthesized by processing fermentation products, such as simvastatin, or some are entirely chemically synthesized, such as flu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More